Optimizing Frontline and Early Relapse Management in Multiple Myeloma: APP Perspectives

This OncLive® Insights program explores evolving approaches to the management of multiple myeloma across frontline and early relapse settings, with a focus on practical considerations for advanced practice providers. Jill Burke, NP, and Tanika Pittman, APRN, discuss the growing role of quadruplet regimens in newly diagnosed multiple myeloma, including patient selection, treatment goals, multidisciplinary assessment, and strategies for educating patients and caregivers. The discussion also addresses treatment duration, toxicity monitoring, infection prevention, supportive care, adherence, shared decision-making, and the role of minimal residual disease assessment in communicating treatment response. Faculty share practical perspectives on anti-CD38 therapy administration, subcutaneous delivery options, clinic workflow, and reducing treatment burden. The conversation then transitions to early relapse, highlighting individualized treatment selection, sequencing considerations, and preparation for teclistamab plus daratumumab, including step-up dosing, safety monitoring, infection risk, and care coordination. The program concludes with practical clinical pearls on the evolving role of APPs in multiple myeloma care.